SCHEMBL20475840

SCHEMBL20475840

CC1(C)O[C@@H]2[C@H](O1)[C@@H](C(=O)c1ccc(Cl)c(Cl)c1)C[C@H]2n1ccc2c(Cl)ncnc21

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 7/20 0.41
▸ SLC22A12 Q96S37 1/20 0.39
▸ PRMT5 O14744 9/20 0.38
▸ WDR77 Q9BQA1 9/20 0.38
▸ KMO O15229 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667489 0.92 NNMT (0.40) NNMTSLC22A12PRMT5WDR77
SCHEMBL30207955 0.92 NNMT (0.40) NNMTSLC22A12PRMT5WDR77
SCHEMBL19667572 0.85 NNMT (0.40) NNMTPRMT5WDR77
SCHEMBL19667606 0.82 PRMT5 (0.41) NNMTPRMT5WDR77
SCHEMBL18205024 0.82 PRMT5 (0.43) SLC22A12PRMT5WDR77
SCHEMBL20475824 0.79 PRMT5 (0.57) PRMT5WDR77
SCHEMBL20488472 0.79 PRMT5 (0.57) NNMTPRMT5WDR77
SCHEMBL20488473 0.79 PRMT5 (0.57) NNMTPRMT5WDR77
SCHEMBL20475825 0.79 PRMT5 (0.57) PRMT5WDR77
SCHEMBL20475859 0.79 PRMT5 (0.57) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-07-14 — — US disclosed
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-07-14 — — US disclosed
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-01-11 — — US disclosed
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-01-11 — — US disclosed
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-05-06 — — US disclosed
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-05-06 — — US disclosed
WO-2020206308-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-10-08 — — WO disclosed
WO-2020206308-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-10-08 — — WO disclosed
WO-2018160824-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2018-09-07 — — WO disclosed
WO-2018152548-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2018-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT6, PRMT1 NNMT 41/4885SLC22A12 4719/4885PRMT5 1/4885
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRMT5, PRMT6, PRMT1 NNMT 65/4885SLC22A12 4418/4885PRMT5 1/4885
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT6, PRMT1 NNMT 41/4885SLC22A12 4719/4885PRMT5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback